Institute of Hematology and Medical Oncology L. e A. Seràgnoli, Policlinico Sant'Orsola-Malpighi, University of Bologna, Via Massarenti 9, Bologna, Italy.
Clin Cancer Res. 2010 Aug 1;16(15):3998-4004. doi: 10.1158/1078-0432.CCR-10-0162. Epub 2010 Jun 11.
This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
From December 2006 to October 2008, 55 high-risk elderly (age > or =60 years) untreated DLBCL patients were treated in seven Italian institutions with a short-course of chemotherapy consisting of four cycles of R-CHOP21 followed by (90)Y-ibritumomab tiuxetan 6 to 10 weeks later.
Of the 55 patients, 48 underwent radioimmunotherapy. The overall response rate to the entire treatment regimen was 80%, including 73% complete remissions and 7% partial remissions. Eight (50%) of the 16 patients who achieved less than a complete response with CHOP improved their remission status after (90)Y-ibritumomab tiuxetan administration. With a median follow-up of 18 months, the 2-year progression-free survival was estimated to be 85%, with a 2-year overall survival of 86%. (90)Y-ibritumomab tiuxetan toxicity consisted of grade 3 to 4 hematologic toxicity in 28 of 48 patients, mainly neutropenia (23 patients) and thrombocytopenia (15 patients). Red cells and/or platelets transfusions were given to three patients.
This study evaluated the feasibility, efficacy, and safety of a short-course R-CHOP21 regimen followed by (90)Y-ibritumomab tiuxetan in high-risk elderly DLBCL patients.
本研究旨在评估在先前未经治疗的弥漫性大 B 细胞淋巴瘤（DLBCL）的高危老年患者中，采用利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松（R-CHOP）短疗程治疗后，使用（90）Y-依鲁替尼替昔单抗治疗的疗效和安全性。
从 2006 年 12 月至 2008 年 10 月，7 家意大利机构对 55 名未经治疗的高危老年（年龄≥60 岁）DLBCL 患者进行了治疗，采用包含四个周期 R-CHOP21 的短疗程化疗，然后在 6-10 周后进行（90）Y-依鲁替尼替昔单抗治疗。
55 例患者中有 48 例接受了放射性免疫治疗。整个治疗方案的总体缓解率为 80%，包括 73%的完全缓解和 7%的部分缓解。在接受 CHOP 治疗后缓解程度低于完全缓解的 16 名患者中，有 8 名（50%）在接受（90）Y-依鲁替尼替昔单抗治疗后改善了缓解状态。中位随访 18 个月时，2 年无进展生存率估计为 85%，2 年总生存率为 86%。（90）Y-依鲁替尼替昔单抗的毒性包括 48 例患者中有 28 例（28%）发生 3-4 级血液学毒性，主要为中性粒细胞减少症（23 例）和血小板减少症（15 例）。有 3 名患者需要输血红细胞和/或血小板。
本研究评估了在高危老年 DLBCL 患者中采用 R-CHOP21 短疗程治疗后，再使用（90）Y-依鲁替尼替昔单抗的可行性、疗效和安全性。
